Study | n | PFS and OS | ≥60 y | Advanced stage | Bulk | IPI | PS ≥ 2 | Threshold | Median (cm3) | IQR (cm3) | Cutoff (cm3) |
Song 2012 (44) | 169 | 3-y PFS, 74; OS, 76 | 60% | 41% | 4% ≥ 5 cm | 26% ≥ 3 | 25% | SUV ≥ 2.5 | 198 | 5–1,991 | 220 |
Sasanelli 2014 (51) | 114 | NA | 31% | 82% | 36% ≥ 10 cm | 65% ≥ 2* | 30% | ≥41% SUVmax | 315 | 4–2,654 | 550 |
Song 2016 (43) | 107 | NA | 67% | 100% | 19% | 81% ≥ 4† | 16% | SUV ≥ 2.5 | 527 | 15–3,549 | 600 |
Cottereau 2016 (49) | 81 | 5-y PFS, 60; OS, 63 | 63% | 80% | 40% ≥ 10 cm | 68% ≥ 2* | 30% | ≥41% SUVmax | 320 | 106–668 | 300 |
Mikhaeel 2016 (13) | 147 | 5-y PFS, 65; OS, 74 | 48% | 69% | 40% ≥ 10 cm | 69% ≥ 2 | 30% | SUV ≥ 2.5 | 595 | 2–7,337 | 400 |
Tout 2017 (66) | 108 | 4-y PFS, 76; OS, 82 | 49¶ | 80% | NA | 60% ≥ 3‡ | NA | ≥41% SUVmax | 313.5 | NA | NA |
↵* Age-adjusted IPI.
↵† National Comprehensive Cancer Network IPI.
↵‡ Modified IPI.
↵¶ Median age.
PFS and OS data refer to percentages of patients.
PFS = progression-free survival; OS = overall survival; IPI = International Prognostic Index; PS = performance status; IQR = interquartile range; NA = not available.